Axogen, Inc.
A maker of surgical products that repair damaged peripheral nerves, Axogen's lineup includes the Avance Nerve Graft (processed human nerve tissue) and the Axoguard line of porcine-based connectors, protectors, and caps used by surgeons to restore feeling and movement. The business grew out of technology licensed from the University of Florida and took its current form after a 2011 merger, with the FDA approving Avance as a licensed biologic in 2025. A neat quirk: before Avance, the standard repair often meant cutting a healthy nerve from elsewhere in the patient's own body, so the fix created a new injury.
Sold 1.15M
Sold 870.8K
Granted 49.0K · Bought 6.5K · Sold 199.6K
Granted 1.27M · Bought 109.2K · Sold 189.1K
Bought 20.0K
Granted 5.5K · Bought 153.2K
Granted 126.9K · Bought 37.0K · Sold 6.0K
Granted 531.5K · Bought 37.9K · Sold 236.7K
Granted 366.6K · Sold 46.1K
Granted 300.0K
Granted 129.0K · Bought 33.3K · Sold 54.4K
Bought 4.0K
Sold 3.9K
Granted 73.7K · Bought 30.0K · Sold 10.0K
Granted 80.8K · Bought 10.0K · Sold 1.15M
Granted 75.7K · Sold 12.2K
Granted 298.4K · Bought 3.3K · Sold 206.4K
Granted 89.2K · Sold 30.3K
Granted 150.0K · Sold 86.5K
Granted 68.9K · Sold 7.4K
Granted 92.5K · Sold 22.5K
Granted 157.3K · Sold 86.4K
Granted 55.0K · Sold 4.1K
Granted 62.4K · Bought 8.5K · Sold 16.1K
Granted 140.8K · Bought 10.0K · Sold 136.5K
Granted 53.8K · Sold 21.4K
Granted 43.7K · Bought 2.0K · Sold 3.2K
Granted 11.8K · Bought 15.5K
Granted 48.3K · Sold 20.0K
Granted 22.2K · Bought 5.6K · Sold 649
Bought 25.0K
Granted 100.1K · Sold 663
Granted 26.5K
Granted 32.3K · Sold 341.5K
Granted 22.4K
Granted 86.3K · Bought 2.5K · Sold 74.6K
Granted 81.2K · Sold 67.1K
Granted 74.7K · Sold 60.5K
Bought 12.8K
Granted 3.9K
Bought 2.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Essex Woodlands Fund IX, L.P.10% owner · 1 transaction | — | 3.71Mas of Nov 2017 | — | — | 1.15M |
| Deerfield Management Co +3 co-filersReporting owner · 6 transactions | — | 3.00Mas of Jul 2016 | — | — | 870.8K |
| Mandato Joseph MDirector · 12 transactions | — | 1.23Mas of Aug 2016 | 49.0K | 6.5K | 199.6K |
| Zaderej Karen L.CEO, Director · 81 transactions | — | 1.14Mas of Mar 2024 | 1.27M | 109.2K | 189.1K |
| Hopfenspirger Larry10% owner · 1 transaction | — | 459.3Kas of Sep 2011 | — | 20.0K | — |
| Harper John FrederickDirector · 3 transactions | — | 356.1Kas of Aug 2013 | 5.5K | 153.2K | — |
| Gold Mark StephenDirector · 38 transactions | — | 305.5Kas of Jun 2022 | 126.9K | 37.0K | 6.0K |
| Freitag Gregory GeneDirector · 65 transactions | — | 283.5Kas of Jun 2024 | 531.5K | 37.9K | 236.7K |
| DeVinney Erick WayneChief Innovation Officer · 76 transactions | — | 262.8K | 366.6K | — | 46.1K |
| Naor NirCFO · 2 transactions | — | 260.9Kas of Jan 2025 | 300.0K | — | — |
| Wendell Amy McBrideDirector · 23 transactions | — | 108.0K | 129.0K | 33.3K | 54.4K |
| Engels John PVP · 1 transaction | — | 98.4Kas of Oct 2016 | — | 4.0K | — |
| Quackenbush DorisSales VP · 1 transaction | — | 96.3K | — | — | 3.9K |
| McCarrey Shawn FSVP Sales · 13 transactions | — | 88.1Kas of Aug 2018 | 73.7K | 30.0K | 10.0K |
| Neels Guido JDirector · 11 transactions | — | 86.7Kas of Jun 2025 | 80.8K | 10.0K | 1.15M |
| Kemp JensChief Marketing Officer · 9 transactions | — | 72.5K | 75.7K | — | 12.2K |
| Mariani Peter JEVP & Chief Financial Officer · 60 transactions | — | 71.6Kas of Dec 2023 | 298.4K | 3.3K | 206.4K |
| Hartley Lindsey MarieCFO · 18 transactions | — | 65.1K | 89.2K | — | 30.3K |
| Dale Michael DChief Executive Officer · 3 transactions | — | 63.5K | 150.0K | — | 86.5K |
| Scopelianos AngeloChief R&D Officer · 32 transactions | — | 58.6Kas of Mar 2024 | 68.9K | — | 7.4K |
| Began Marc AEVP & General Counsel · 11 transactions | — | 54.6K | 92.5K | — | 22.5K |
| Donovan Michael PatrickVP Operations · 59 transactions | — | 54.3Kas of Mar 2024 | 157.3K | — | 86.4K |
| Levine Alan MDirector · 8 transactions | — | 50.9K | 55.0K | — | 4.1K |
| Rudelius Robert JamesDirector · 14 transactions | — | 48.2Kas of Sep 2020 | 62.4K | 8.5K | 16.1K |
| Burke William P. Mr.Director · 26 transactions | — | 38.7K | 140.8K | 10.0K | 136.5K |
| Thomas PaulDirector · 7 transactions | — | 32.4K | 53.8K | — | 21.4K |
| Martinez Maria D.Chief Human Resources Officer · 31 transactions | — | 30.5Kas of Oct 2023 | 43.7K | 2.0K | 3.2K |
| Blackford Quentin S.Director · 6 transactions | — | 27.3Kas of Mar 2022 | 11.8K | 15.5K | — |
| Hansen David KVP Finance & Treasurer · 8 transactions | — | 25.6Kas of May 2019 | 48.3K | — | 20.0K |
| Billet IsabelleChief Strategy and BD Officer · 31 transactions | — | 25.4Kas of Dec 2022 | 22.2K | 5.6K | 649 |
| Johnston Lee Robert JrChief Finacial Officer · 11 transactions | — | 24.7Kas of Jun 2015 | — | 25.0K | — |
| Friedman Mark LouisVP Regulatory Affairs & Policy · 39 transactions | — | 24.3Kas of Mar 2022 | 100.1K | — | 663 |
| Ottinger BradleyGeneral Counsel and CCO · 8 transactions | — | 23.7Kas of Mar 2023 | 26.5K | — | — |
| Grooms Jamie MarkDirector · 18 transactions | — | 19.1Kas of Sep 2018 | 32.3K | — | 341.5K |
| Sandberg EricChief Commercial Officer · 12 transactions | — | 16.1Kas of Jul 2022 | 22.4K | — | — |
| Tyndall Joseph A.Director · 15 transactions | — | 14.2K | 86.3K | 2.5K | 74.6K |
| Weiler Kathy JohnsonDirector · 10 transactions | — | 14.2K | 81.2K | — | 67.1K |
| Johnson JohnDirector · 13 transactions | — | 14.2K | 74.7K | — | 60.5K |
| Schiaparelli Jill FSVP, Bus. Strategy&Marketing · 7 transactions | — | 12.8Kas of May 2014 | — | 12.8K | — |
| Gingrich Jon S.Chief Commercial Officer · 2 transactions | — | 4.2Kas of Feb 2019 | 3.9K | — | — |
| Leach KevinVice President Marketing · 1 transaction | — | 2.0Kas of Oct 2016 | — | 2.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -4.59M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.